Patients with hepatic and renal insufficiency.
Use in pregnancy & lactation: Isotretinoin is highly teratogenic. Therefore, it is contraindicated in women who are pregnant or who may become pregnant. The female patient should have negative pregnancy test 2 weeks prior to the start of therapy. The patient should use effective contraception without any interruption for 1 month before beginning therapy, during therapy and for 1 month following discontinuation of therapy.
Isotretinoin is contraindicated in nursing mothers.